Dottikon ES Holding Valuation

Is DESNZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DESNZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DESNZ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DESNZ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DESNZ?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for DESNZ. This is calculated by dividing DESNZ's market cap by their current preferred multiple.
What is DESNZ's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CHF 3.33b

DESNZ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	9.7x
Enterprise Value/EBITDA	28.9x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does DESNZ's PE Ratio compare to its peers?

The above table shows the PE ratio for DESNZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	26.8x
HIK Hikma Pharmaceuticals	18.8x	12.7%	UK£4.2b
GSK GSK	23.1x	21.7%	UK£57.9b
ANCR Animalcare Group	31.1x	15.8%	UK£143.7m
AZN AstraZeneca	34.3x	16.5%	UK£170.9b
DESNZ Dottikon ES Holding	41.3x	n/a	CHF 3.3b

Price-To-Earnings vs Peers: DESNZ is expensive based on its Price-To-Earnings Ratio (41.3x) compared to the peer average (26.8x).

Price to Earnings Ratio vs Industry

How does DESNZ's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.2%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.2%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: DESNZ is expensive based on its Price-To-Earnings Ratio (41.3x) compared to the European Pharmaceuticals industry average (20.6x).

Price to Earnings Ratio vs Fair Ratio

What is DESNZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DESNZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	41.3x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate DESNZ's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.